T. Rowe Price Group

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Form Energy, Inc. is a company focused on developing long-duration energy storage systems aimed at transforming the electric grid by enabling the reliable use of renewable energy sources such as wind and solar. Established in 2017 and based in Somerville, Massachusetts, Form Energy is known for its innovative iron-air battery technology, which allows for the storage of electricity over extended periods, making renewable energy more dispatchable throughout the year. This technology not only helps to replace conventional fossil fuel-based generation but also enhances transmission capacity without the need for new infrastructure. By facilitating deep decarbonization of the electric system, Form Energy plays a significant role in reducing carbon emissions and promoting a sustainable energy future.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Kymera Therapeutics is a biotechnology company focused on targeted protein degradation. It employs a proprietary predictive modeling platform to discover novel small molecule therapeutics that selectively degrade disease-causing proteins.

Cross River Bank combines traditional banking with innovative technologies to create compliant financial solutions for fintech companies. It offers personal and corporate banking services, direct lending loans, marketplace lender solutions, flash disbursements, and financial technology solutions.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

DataRobot develops an automated machine learning platform that enables users across various industries to build predictive models. Its cloud-based solution, DataRobot Cloud, offers a project-based curriculum for gaining insights from data scientists. The company also provides DataRobot MLOps for deploying and managing machine learning models, along with enterprise features like flexible deployment and governance in its DataRobot Enterprise solution.

Thrive Earlier Detection is a healthcare company dedicated to saving lives through early detection of cancer. It develops CancerSEEK, a liquid biopsy test designed to identify various cancers in their earliest stages via blood analysis.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

C4 Therapeutics is a biopharmaceutical company developing targeted protein degradation therapies using its proprietary Degronimid platform. This platform enables the selective destruction of disease-causing proteins, expanding the scope of treatable conditions and potentially reducing drug resistance. The company focuses on oncology indications and has strategic collaborations with industry leaders.

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing next-generation antiviral therapeutics for severe viral diseases. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by the SARS-CoV-2 virus. Additionally, Atea is advancing several candidates in clinical trials, including AT-787 for hepatitis C and AT-752 for dengue, both in phase 2 trials. The company aims to provide innovative treatments for infections caused by RNA and DNA viruses, improving outcomes for patients suffering from serious viral infections. Atea Pharmaceuticals was incorporated in 2012.

Founded in 2015 by Joe Spinelli, HaulHub specializes in a project management platform tailored for heavy construction companies. This platform streamlines transportation and digital ticketing processes, serving material producers, general contractors, fleet owners, and carriers nationwide.

Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Toast is a cloud-based point-of-sale and restaurant-management platform for the food service and hospitality industry. It offers an end-to-end system that combines front-of-house and back-of-house functionality, including tableside ordering, online ordering, delivery tracking, labor management, and real-time reporting. The platform serves a broad range of establishments such as restaurants, bakeries, cafes, bars, nightclubs, and pizzerias, with a focus on mid-market operators primarily in the United States. Toast generates revenue from the sale of restaurant-grade hardware and recurring subscriptions and services tied to transaction volume. As of fiscal 2024, it served approximately 134,000 restaurant locations, and its typical customer generates slightly more than $1 million in annual revenue. The company is headquartered in Boston and maintains additional offices in Portland, Oregon; Omaha, Nebraska; and Dublin, Ireland.

Toast is a cloud-based point-of-sale and restaurant-management platform for the food service and hospitality industry. It offers an end-to-end system that combines front-of-house and back-of-house functionality, including tableside ordering, online ordering, delivery tracking, labor management, and real-time reporting. The platform serves a broad range of establishments such as restaurants, bakeries, cafes, bars, nightclubs, and pizzerias, with a focus on mid-market operators primarily in the United States. Toast generates revenue from the sale of restaurant-grade hardware and recurring subscriptions and services tied to transaction volume. As of fiscal 2024, it served approximately 134,000 restaurant locations, and its typical customer generates slightly more than $1 million in annual revenue. The company is headquartered in Boston and maintains additional offices in Portland, Oregon; Omaha, Nebraska; and Dublin, Ireland.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Sweetgreen is an American fast-casual restaurant chain founded in 2007 that serves plant-forward, seasonal salads and grain bowls prepared in-house from fresh ingredients. The company operates a nationwide network of restaurants and sells gift cards and branded merchandise online, reflecting its focus on accessible, healthy dining. It emphasizes organic, regenerative and local sourcing to offer transparent, high-quality meals at scale, aiming to be as ubiquitous as traditional fast food without compromising quality. Sweetgreen is guided by a mission-driven stance and maintains partnerships with community organizations such as FoodCorps to support broader food and nutrition initiatives.

aTyr Pharma is a biotherapeutics company focused on discovering and developing protein biologics for human therapeutics. Its primary program, ATYR1923, is a clinical-stage product candidate designed to modulate immune engagement in interstitial lung diseases.

Lookout, Inc. is a cybersecurity company specializing in cloud-based technology solutions for mobile security. Founded in 2005 and headquartered in San Francisco, California, with additional offices in major cities worldwide, Lookout offers a range of products including mobile security apps for both Android and iOS devices. Its solutions encompass Mobile Threat Protection, a Mobile Intelligence Center for real-time threat investigations, and an App Vetting API designed to secure enterprise and commercial app stores. By providing organizations with tools to enable bring-your-own-device (BYOD) policies, ensure compliance, and combat advanced mobile threats, Lookout empowers enterprises and individuals to safeguard their sensitive data across devices, applications, networks, and clouds. The company's platform is trusted by various enterprises, government agencies, and millions of consumers, allowing them to manage their data securely and efficiently.

Founded in 2002, Wayfair is a leading online retailer of home goods, offering over 30 million products across furniture, decor, kitchenware, and more. Headquartered in Boston with offices globally, the company operates under several brands including Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

As of January 2001, AllAdvantage Inc. went out of business. AllAdvantage.com, Inc. operates as an Internet advertising company. It pays its users/members a portion of the advertising revenue generated by their online viewing habits. The company also allows members to receive membership benefits that include sponsor discounts and rebates for surfing the Web. In addition, it provides incentives for advertisers to build one-on-one relationships with its members. The company was founded in 1999 and is based in Hayward, California with additional offices in Atlanta, Boston, Chicago, Dallas, Detroit, Hayward, London, Los Angeles, New York, Paris, Seattle, Sydney, and Washington DC.